* ARIANA PHARMACEUTICALS *
2003 - IDF
Paris
www.arianapharma.com Contract, Knowledge
Key words: Discovery acceleration, Virtual screening, Knowledge management, Decision support, KEM, eADMET, Bioassays
Mission: to provide decision-support tools, in order to accelerate drug discovery of third parties
Clients: Pharmaceutical industry, Biotechs
info@arianapharma.com
Age: 8 year(s)
Identity| TYPE/MANAGEMENT/INVESTORS | FINANCES/STATUS |
|---|
| Spin-off |
Managing Dir.-CEO: Afshar (Mohammad) [co-founder, born 1966, Ph.D. biochemistry, ex-RiboTargets]
Sc.Dir.-CSO:
Tech.Dir.-CTO: Petitet (François) [Pharm.D., Ph.D., ex-Aureus, Aventis, Rhône-Poulenc-Rorer]
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): privately owned, Institut Pasteur, Vizille Capital Innovation | Turnover (M€) : none (2007)
Total funding (M€) : 1.5
Last funding (M€) : 1.5
Focus : Data
Position : Subcontractor
Company confirm : none |
History | DATE | MILESTONE | TYPE | TIME |
|---|
| 2010 .11 | R&D partnering with Bio-Rad, INSERM and Beaujon Hospital on Hepachronix project, for new biomarkers | R&D | [7 years] |
| 2010 .02 | R&D partnering with Fovea on Phase II clinical data analysis, with KEM clinicals, a new version of its decision support platform KEM (undisclosed fees) | R&D | [6 years] |
| 2009 .08 | Financing (no interest loan) : 10.0 M€, by OSEO Innovation, for oncology biomarker program IMAkinib (with Oncodesign and Guerbet) [Ariana part : 1.0 M€] | DEBT | [6 years] |
| 2008 .07 | 1st round-financing : 1.5 M€, by Vizille Capital Innovation (Crédit Mutuel - CIC) | RFINA | [4 years] |
| 2008 .03 | Launch of new KEM multi-objective data analysis and decision support | MKTG | [4 years] |
| 2005 .12 | Licensing-out of KM platform to Institut Pasteur, against a minority share | LICOUT | [2 years] |
| 2003 .08 | Company founded by Mohamma Afshar and others, as a spin-off from Institut Pasteur | ORGF | [0 year] | Actualisation / Updating: 21-Sep-2011 |
|
